Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Inj. Zoledronic Acid: Test Group-
Tab. Calium 1000mg/day+
Tab Calcitriol 0.25micro gram twice daily +
Injection Zoledronic acid 5 mg once a year.
Control Intervention1: Tab Calcium
Sponsors
Pt BD Sharma PGIMS Rohtak
Eligibility
Inclusion criteria
Inclusion criteria: Either gender adult patients with Osteoporosis with liver cirrhosis
Exclusion criteria
Exclusion criteria: Hyperparathyroidism Acute Kidney Injury Diabetes, Chronic kidney disease Patients on corticosteroids, antiepileptics, antitubercular drugs Hyperparathyroidism, malabsorption disorders Thyroid disorders Hepatocellular carcinoma/ any other malignancy Postmenopausal, pregnant/lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Changes in Bone mineral Density 2. Fracture risk assessment score (FRAX Score)Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of pathological fracture 2. Effect on quality of life using IOF Quellafo 41, EQ 5D-3L, EQ VAS questionnaires 3. Changes in biochemical parameters- Vitamin D levels, ALP, 24hours urone calcium levels. Timepoint: 1. 1 year 2. 1 years 3. 3,6,9,12 months. | — |
Countries
India
Contacts
Public ContactDr Deepak Nehra
Pt BD Sharma PGIMS Rohtak
Outcome results
None listed